. . "10"^^ . "15110" . "10"^^ . . . "SKOUMALOV\u00C1, Ivana" . "ADAM, Tom\u00E1\u0161" . "Barcelona, Spain" . . "Divok\u00E1, Martina" . . "UHPLC-TMS; correlation; treatment response; imatinib plasma levels"@en . . . . . "Pavia" . "Faber, Edgar" . . "Ro\u017Emanov\u00E1, \u0160\u00E1rka" . "RIV/61989592:15110/10:10215602" . "FRIEDECK\u00DD, David" . . . "P(NS9627), P(NS9949)" . . . . "Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment." . . "Haematologica: the hematology journal" . . "Indr\u00E1k, Karel" . "Jaro\u0161ov\u00E1, Marie" . "2"^^ . "RIV/61989592:15110/10:10215602!RIV11-MZ0-15110___" . "Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment."@en . "ROHO\u0147, Peter" . "MI\u010COV\u00C1, Kate\u0159ina" . . . "2010-06-10+02:00"^^ . . "[BB5E5DD02710]" . "0390-6078" . . "In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response." . "In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response."@en . "Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment." . "Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment."@en . "270063" . . "000279051301143" . . . . . "Fondazione Ferrata Storti" .